Anacetrapib - Merck
Alternative Names: Anacetrapib; MK-0859Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Developer Merck & Co; University of Oxford
- Class Antihyperlipidaemics; Oxazolidinones; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
Most Recent Events
- 01 Aug 2018 Discontinued - Phase-II for Hyperlipoproteinaemia type IIa (Adjunctive treatment, Monotherapy) in USA (PO)
- 01 Aug 2018 Discontinued - Phase-III for Atherosclerosis (Adjunctive treatment) in Canada, Italy, Finland, Denmark, Sweden, United Kingdom, Germany, Austria, Spain, USA, Russia, Norway, New Zealand, Mexico, Malaysia, Israel, Australia, Netherlands, France, Hungary, China (PO)
- 01 Aug 2018 Discontinued - Phase-III for Hypercholesterolaemia (Adjunctive treatment) in Spain, Slovakia, Romania, Poland, Israel, Canada, Mexico, Taiwan, Russia, South Korea, Turkey, Bulgaria, Puerto Rico, Hungary, Germany, United Kingdom, Netherlands, USA (PO)